SAM #36C25726Q0797

Sole Source Modification for Increased Xofigo (radium Ra 223 dichloride) Supply

This notice announces the Department of Veterans Affairs, Network Contracting Office 17's intent to modify an existing sole source purchase order for Xofigo (radium Ra 223 dichloride). - The modification increases the quantity of Xofigo from 610 to 1,270 units - Xofigo is a radiopharmaceutical used in VA healthcare facilities - The delivery period is extended through February 28, 2027 - Cardinal Health 414, LLC is the sole source distributor for this product - Xofigo is manufactured by Bayer - This is not a competitive solicitation; objections must be submitted if any vendor believes they can meet the requirement - If no objections are received, the modification will be awarded to Cardinal Health 414, LLC - The opportunity is for increased supply and extended delivery of a specialized pharmaceutical product

Description

Special Notice Notice of Intent to Award a Sole Source Procurement

The Department of Veterans Affairs, Network Contracting Office 17, intends to conduct a sole source award action with Cardinal Health 414. LLC for the following item:

Modification against purchase order 36C25726P0170. The proposed modification is to increase the quantity in the order: Xofigo® (radium Ra 223 dichloride): Increase Quantity: from 610 to 1,270

The proposed modification will also extend the delivery period to 2/28/2027.

This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice. If no affirmative written response is received within 5 business days from the publication of this notice, the proposed modification request will be forwarded to Cardinal Health 414, LLC without any further notice.

View original listing